Emerg Infect Dis by Zell, Roland et al.
LETTERS
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 10, October 2006 1607
biologic results. Since both strains
were identified as L. pneumophila
serogroup 1, we performed sequence-
based typing (SBT) (3) of 6 genes
(flaA, pilE, asd, mip, mompS, and
proA) by using the protocol and data-
base of EWGLINET. Both isolates
showed identical SBT patterns
(2,3,18,15,2,1).
Isolates from 4 patients in the
Zaragoza outbreak were identified at
the Spanish Reference Laboratory as
L. pneumophila serogroup 1
(Philadelphia monoclonal antibody
type) and had identical SBT patterns
(3,4,1,1,14,9). Collaboration between
public health authorities in France and
Spain enabled us to eliminate the
association of patient 2 with the
Zaragoza outbreak and establish an
association of both patients with the
same site in France. Control measures
were taken at the hotel, but we could
not obtain environmental cultures for
comparison with those of the patients.
Lack of environmental data prevented
investigation of the relationship with
the other accommodation sites visited.
The SBT method provides robust
genotyping with high discriminatory
power (index of discrimination >0.94)
(3). This method is less effective at
discriminating between strains than
pulsed-field gel electrophoresis (4),
but it shows excellent reproducibility
and may be useful in epidemiologic
investigation of outbreaks caused by
L. pneumophila. The availability of an
online database with accessible infor-
mation is key for sharing results and
determining the geographic distribu-
tion of isolates that cause
Legionnaires’ disease (4,5).
This study demonstrates the criti-
cal role of sharing results between
countries that participate in a network.
Agreement is essential on a standard-
ized questionnaire that includes more
information on the patient’s exposure
to a disease. Moreover, despite the
performance of the urine antigen test,
cultures of clinical samples should be
encouraged by clinicians and microbi-
ologists. This step would permit use
of techniques, such as SBT, in refer-
ence laboratories and sharing of
results. Our investigation would have
been more difficult without this tech-
nique in identifying the site where the
infection potentially originated.
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To the Editor: Recently, Chen and
co-workers described the expression
of an 11th influenza A virus protein,
designated PB1-F2 because this pro-
tein is encoded in the +1 open reading
frame of the segment-2 RNA (1).
Later, Chen et al. presented a prelimi-
nary analysis of 336 PB1 sequences
from GenBank (2). We have extended
the work on PB1-F2 and analyzed
1,864 partial and complete segment-2
sequences deposited in GenBank;
these sequences belong to 79 influen-
za A virus subtypes. In summary, the
following 8 observations should
receive attention: 
First, the size of PB1-F2 polypep-
tides ranges from 79 to 101 amino
acids (aa); most isolates encode ver-
sions of either 87 or 90 aa. Because
polypeptides of 79 aa are located
within mitochondria, their truncation
has no effect on the protein function.
The frequency of the 79-aa PB1-F2 is
≈5%.
Second, a functional PB1-F2 is
expressed by 92% of all segment-2
sequences, i.e., a polypeptide >78 aa.
The proportion of intact PB1-F2
varies according to host (humans
90%, swine 76%, other mammals
100%, birds 95%).
Third, the H1N1 subtype compris-
es 3 genetic lineages. One clade has 2
branches: 1 branch includes the
human viruses, with the pandemic
1918 virus at its root; the other branch
includes the classic swine viruses.
The third clade represents the
European porcine isolates. Although
all classic swine sequences have a
truncated PB1-F2 (in-frame stop
codons after 11, 24, and 35 codons),
the early human isolates (H1N1
sequences from 1918 through 1947)
have an intact PB1-F2. After 1956,
however, a mutation became preva-
lent such that the recent sequences
starting from A/Beijing/1/56 termi-
nate after 57 codons. An exception to
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this rule is A/Taiwan/3355/97. Two
human H1N1 isolates with an intact
PB1-F2 coding sequence cluster in
the H3N2 clade (A/Kiev/59/79,
A/Wisconsin/10/98). The PB1
sequences of European porcine
influenza A virus isolates cluster with
European porcine H3N2 and H1N2.
Fourth, all H2N2 sequences are
monophyletic and encode an intact
PB1-F2. Fifth, the main sequence
cluster of the H3N2 subtype compris-
es 3 branches: 1) porcine H3N2 and
porcine H1N2 sequences from the
United States, 2) porcine H3N2 iso-
lates from Hong Kong and human
H1N2, and 3) recent human H3N2
and some Japanese H3N2 isolates.
Most of these sequences encode an
intact PB1-F2.
Sixth, the cluster of European
porcine influenza A virus isolates
comprises the subtypes H1N1, H1N2,
and H3N2. The lack of distinct clades
for each subtype indicates frequent
reassortment in the evolution of these
viruses. Of the segment-2 sequences,
56% encode an intact PB1-F2.
Seventh, other porcine isolates of
various subtypes represent trans-
species infections or single reassort-
ment events. And eighth, the seg-
ment-2 sequences of many avian
influenza A virus isolates encode
intact PB1-F2. Considerable propor-
tions of truncated PB1-F2 genes were
found in the H5N2, H6N6, H9N2,
and H13N2 subtypes. However,
because of the small number of
sequences available, this observation
may not be important.
In conclusion, PB1-F2 is
expressed in most avian and many
porcine influenza A virus isolates.
This finding contrasts with those in
the initial publication, which stated
that PB1-F2 is not expressed in many
animal isolates, particularly those of
porcine origin (1). Because PB1-F2
was described as a proapoptotic pro-
tein probably counteracting the host
immune response, why numerous
human and porcine isolates lack this
protein without selective disadvan-
tage remains unclear.
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In response: Zell et al. (1) per-
formed an extensive genetic investi-
gation of PB1-F2, based on up-to-date
GenBank sequences. Their sample
size (1,864) greatly outnumbered ours
(336) in a previous study (2) and thus
definitely better portrays the genetic
characteristics of PB1-F2. We appre-
ciate their analyzing these samples by
subdividing nonhuman strains into
different species, which we did not do
(2). Their analysis is especially mean-
ingful for the global pandemic threat
from avian influenza viruses, which
increases the need to study inter-
species adaptation and transmission. 
Zell et al. found that 92% of PB1
RNA encodes a functional PB1-F2,
compared with our 79% (264/334),
which supports the increasingly cru-
cial role of PB1-F2 in influenza virol-
ogy. They found the proportion of
intact human PB1-F2 to be 90%, a
substantial boost from our 68%
(67/99), which was based on data
from late 2003 (2). This increase is
apparently caused by the increasing
number of human H3N2 sequences
(mostly encoding an intact PB1-F2
compared with H1N1) deposited in
the past 2 years. 
Human H1N1 from 1918 through
1947 contains full-length PB1-F2,
whereas human H1N1 beginning in
1956 has a truncated PB1-F2 after
codon 57. As reported by Zell et al.,
only 3 human H1N1 strains contain
full-length PB1-F2: A/Kiev/59/79,
A/Taiwan/3355/97, and A/Wisconsin/
10/98. The PB1 genes of A/Kiev/
59/79 and A/Wisconson/10/98 were
found clustered with human H3N2 as
a result of natural reassortment
between human H1N1 and H3N2
strains. On the other hand, the asyn-
onymous mutation found on
A/Taiwan/3355/97 enabled the trans-
lation to get past the usual stop codon
at position 58, which other H1N1
strains exhibit. A/Taiwan/3355/97
(H1N1) was isolated from a patient
with severe pneumonia. Animal study
has demonstrated that the existence of
full-length PB1-F2 contributed to
pathogenesis in mice (3). We specu-
late that the expression of a full-length
PB1-F2 may contribute to disease
severity in humans. 
The C-terminal domain of PB1-F2
contains the mitochondrial signal and
can trigger apoptosis in specific
immune-related cells. Our recent
work (4) comparing avian and human
influenza A viruses also found that
many species-associated amino acid
signatures are located on the C termi-
nal of PB1-F2. This finding highlights
the importance of further investigat-
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To the Editor: Although most
human enterovirus (EV) (genus
Enterovirus, family Picornaviridae)
infections are asymptomatic, they can
cause upper respiratory illness, febrile
rash, aseptic meningitis, pleurodynia,
encephalitis, acute flaccid paralysis,
and neonatal sepsislike disease (1).
Most EVs have been implicated in
aseptic meningitis, most notably
echovirus (E) 30, 9, 6, and 11 and
coxsackie B virus (CBV) type 5 (2);
other serotypes are less frequently
associated with neurologic disease.
New EV serotypes have come to
light, chiefly as a result of molecular
typing methods (3–6). EV75 was pro-
posed as a new serotype of the EV
genus in 2004 (5). Retrospective
analysis showed that it had circulated
sporadically in Asia, the United
States, and Africa since at least 1974.
Only 8 isolates of this serotype have
been reported worldwide, in 1974,
1985, 1986, 1987 (n = 2), 1998, and
2000 (n = 2). Infection in those cases
was associated with respiratory dis-
ease, acute flaccid paralysis, neonatal
jaundice, failure to thrive, or unspeci-
fied neurologic disease or was asymp-
tomatic. At the time of writing this
manuscript, EV75 had not been linked
to aseptic meningitis.
From May 2005 through January
2006, 106 EVs were received for typ-
ing from Spanish hospital laborato-
ries; 46 of them were from patients
with aseptic meningitis, 10 from
patients or contacts of patients with
acute flaccid paralysis, 27 from
patients with fever, 7 from patients
with respiratory diseases, and 16 from
other patients. Twenty EVs could not
be typed by serum neutralization (7);
however, 3′ terminus VP1 gene
sequence analysis (8) showed that
they were E18 (n = 7), CBV3 (n = 1),
and E16 (n = 2); 2 could not be typed
with serologic or molecular methods
because the 3′ terminus of VP1 gene
amplification was negative. The
analysis of the 3′ terminus of VP1
gene of the remaining 5 cerebrospinal
fluid (CSF) and 3 nasopharyngeal iso-
lates showed that they were similar to
the recently proposed EV75 serotype
(5). These 8 isolates were obtained
from samples from children in Bilbao
(n = 3), Granada (n = 3), Barcelona (n
= 1), and the Canary Islands (n = 1).
In 4 patients with aseptic meningitis,
EV75 was isolated from CSF. EV75
was isolated from CSF of a fifth
patient who had symptoms of fever
and irritability. The remaining 3 EV75
isolates were from nasopharyngeal
swabs of children who had fever, res-
piratory disease, or gastroenteritis. All
isolates were grown in cell lines
(rhabdomyosarcoma, lung adenocar-
cinoma, and human fetal lung fibrob-
last) and identified as EV by immuno-
fluorescence with pan-EV antibody
assays (Pan Entero Blend Chemicon,
Temecula, CA, USA, and Monoclonal
Mouse Anti-Enterovirus, Dako,
Glostrup, Denmark).
Phylogenetic analysis of the iso-
lates from 2005 was performed on the
basis of complete VP1 gene sequence
(GenBank accession nos. DQ468137–
DQ468142). The 5′ terminal domain
was obtained by reverse transcrip-
tase–PCR with specific primers
EV75_sense: 5′-GAAAGCTTYTTC-
CAAGGGGA-3′ and EV75_anti: 5′-
GAGAAGTGKGACCAWCCATC-
3′. Phylogenetic analysis of the
Spanish isolates and representatives
of all other species B EVs showed that
the Spanish isolates clustered (boot-






ding to the proposed EV75. The
Spanish isolates constitute a subgroup
(bootstrap value 100, Figure). The
similarity between the Spanish cluster
and other EV75 isolates was
82.8%–85.4% at the nucleic acid
level. Although the entire VP1
sequence was not available for the
isolates from 2006, the VP1 3′ termi-
nal analysis showed the strains
belonged to the same cluster.
To our knowledge, this is the first
isolation of EV75 in Spain. Indeed,
isolation of EV75 has not been report-
ed in Europe. Given that the European
EV75 isolate grows easily in a variety
of cell lines, is detected by common
EV genus-specific antibodies, and that
EV surveillance and typing were per-
formed in Spain since 1988 (2), EV75
might have begun to circulate in Spain
recently. However, because isolates
are not obtained from all aseptic
meningitis patients and many EVs are
detected by PCR but never typed, we
cannot rule out the possibility of previ-
ous asymptomatic circulation.
The European strains of EV75
appear to represent a different evolu-
tionary lineage than those previously
